IBIO earnings call for the period ending December 31, 2020.
News & Analysis: iBio
One analyst says investors are underappreciating the biotech's growth prospects.
Innovation paid off big for investors.
The time to make money by investing in iBio is over. Here's why that's good news.
Here's what it would take.
These companies are certainly risky, but they might have what it takes to deliver serious growth for investors.
The company is advancing its most-promising vaccine candidate for the novel coronavirus.
The biotech struck a licensing deal for a potential coronavirus treatment.
It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.
The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.